Anton Hagenbeek, MD, PhD from University of Amsterdam, Netherlands provides a summary of two press briefings held at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark. Prof. Hagenbeek discusses some exciting data provided from the groundbreaking, Phase III, randomized POLLUX trial of daratumumab combined with lenalidomide and dexamethasone in multiple myeloma (MM), presented by Dr Meletios Dimopolos (NCT02076009). Prof. Hagenbeek explains how the new antibody daratumumab combined with lenalidomide and dexamethasone showed a significant improvement in progression-free survival (PFS), with the chance of relapsing or progressing reduced by 63%. Prof. Hagenbeek therefore believes it will be the standard of care for multiple myeloma (MML) from now on. Prof. Hagenbeek further discusses data on BiTE antibodies infusion on acute lymphoblastic leukemia (ALL) reported by Dr Max Topp. He mentions how overall survival (OS) in these patients doubled, compared to patients who did not take the antibody, providing a significant contribution to the field of acute leukemia. Prof. Hagenbeek discusses the EURO-SKI study in chronic myeloid leukemia (CML) presented by Dr Johan Richter (NCT01596114). The data showed half the patients were found to remain in molecular remission after they stopped taking tyrosine kinase inhibitors (TKI).